Broshy Eran 的 Form 4/A 修正申報
修正Theravance Biopharma, Inc.（TBPH），2025/11/14 申報
- 申報編號
- 0001256230-25-000007
- 申報時間
- 2025/11/14
- 交易日
- 2025/11/11
- 申報延遲
- 3 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2025/11/13
這份申報列了 3 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $80.9 萬。交易後 3 天申報。
這份修正申報取代了 0001256230-25-000006（2025/11/13 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Broshy EranCIK 0001256230 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/11/11 | Ordinary Shares | M行使選擇權取得 | +14,000 | $10.15 | +$142,100 | 107,878 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
表 I 有 2 筆交易的價格引用這則附註。
- F2
The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.
表 I 有 1 筆交易的價格引用這則附註。
- F3
This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).
備註
This Form 4/A is being filed to correct an administrative error in the number of Ordinary Shares reported as sold at $18.50 on November 11, 2025. The originally reported amount of 29,500 shares in Table I, Row 1 was incorrect; the correct amount is 15,500 shares. The number of Ordinary Shares beneficially owned following the transactions has been correspondingly adjusted in all three rows of Table I.